Clarification on Anthrax Vaccine Immunization Program (AVIP) Authorization
This MARADMIN clarifies the Anthrax Vaccine Immunization Program (AVIP) authorization policy for Marines receiving orders to deploy to high threat areas. It authorizes personnel with orders to units preparing to deploy or already deployed to high threat areas to receive AVIP immunizations prior to detaching from their current commands, ensuring all deploying forces are adequately immunized before arrival.
Issued: January 6, 2003
1. BACKGROUND. CMC PROVIDED AVIP IMPLEMENTATION GUIDANCE FOR USMC FORCES IN REF A. DEPSECDEF AUTH IMMUNIZATION OF SELECT FORCES IN PRIORITY GROUP 3 VIA CLASSIFIED MEMO (REF B). CMC AUTH IMMUNIZATION OF SELECT USMC PRIORITY GROUP 3 FORCES VIA CLASSIFIED MSG (REF C). INFORMATION ON THE AVIP PRIORITY GROUPS AND HIGHER THREAT AREAS MAY BE OBTAINED FROM THE HQMC PPO SIPR HOMEPAGE WWW.HQMC.USMC.SMIL.MIL/PLN/PLN_HOME.HTM. ADDITIONAL INFORMATION ON AVIP AND OTHER VACCINE PROGRAMS MAY BE VIEWED AT WWW.VACCINES.ARMY.MIL. 2. PURPOSE. TO CLARIFY POLICY SET FORTH IN REF A, PARA 3, AND REF C, PARA 3.A. 3. COMMANDANT'S INTENT. ENSURE ALL DEPLOYING FORCES ARE ADEQUATELY IMMUNIZED PRIOR TO ARRIVAL IN HIGH THREAT AREAS (HTA), I.E., PERSONNEL HAVE RECEIVED A MINIMUM OF THE FIRST THREE DOSES OF ANTHRAX VACCINE OR IF RESTARTING THE VACCINE ARE CURRENT (UP-TO-DATE) AS DEFINED BY THE FDA-APPROVED DOSING SCHEDULE. 4. EXECUTION. PERSONNEL IN RECEIPT OF ORDERS TO UNITS PREPARING TO DEPLOY OR ALREADY DEPLOYED TO HTAS ARE AUTH TO RECEIVE AVIP IMMUNIZATIONS PRIOR TO DETACHMENT FROM THEIR CURRENT COMMANDS. COMMANDERS WILL ENSURE THAT IDENTIFIED MARINES' FUTURE COMMAND, AS CLARIFIED IN REFS A, B AND C, IS AUTH TO RECEIVE ANTHRAX IMMUNIZATIONS AND THAT MARINES ARE AVAILABLE FOR SUBSEQUENT AVIP IMMUNIZATIONS PER THE FDA-APPROVED IMMUNIZATION SCHEDULE. COMMANDERS SHALL PROVIDE A LETTER OF AUTHORIZATION FOR AVIP IMMUNIZATION IF REQUIRED BY THE MEDICAL TREATMENT FACILITY. MEDICAL PERSONNEL WILL CONTINUE TO VACCINATE AND DOCUMENT ALL AVIP IMMUNIZATIONS PER PREVIOUSLY PUBLISHED ADMIN AND CLINICAL GUIDANCE. 5. EXPIRATION DATE: INDEFINITE.